First Person (OTCMarkets: QRON), a cognitive performance and functional wellness brand and wholly owned subsidiary of Qrons, announced its next phase of growth, driven by early consumer momentum for Think Fast™, a premium functional coffee using proprietary Crystallized Lion's Mane technology.
Think Fast™ combines single-origin Costa Rican coffee, supplied by a strategic partner, with First Person's soluble, tasteless lion's mane extract. The company is broadening its positioning from traditional wellness to cognitive performance, active lifestyles and productivity, targeting everyday moments requiring focus, mental readiness and performance.
According to First Person, a preliminary, single-participant, unblinded evaluation at Peak Brain Institute using qEEG and IVA-2 testing observed an approximately 26% increase in overall attention score, a 28% improvement in visual reaction time, and higher alpha peak frequency, though these results do not establish causation or clinical efficacy and may not generalize.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Qrons Inc. (OTCQB:QRON) has filed an International Patent Application for its innovative Therapeutic Polypseudorotaxane Hydrogels, aimed at treating traumatic brain injuries and other nervous system conditions. Filed on March 12, 2023, the patent application number is PCT/IB2023/052368. The technology promises to support neuronal damage treatment and regeneration, with potential applications extending beyond traumatic brain injuries. CEO Jonah Meer emphasizes the significance of this filing in advancing their intellectual property and research initiatives. Qrons focuses on strategic partnerships to enhance its biotechnology developments, particularly in Israel, known for its biotech innovations.
Qrons Inc. (OTCQB:QRON) has announced a collaboration with a major public research university in Israel to explore the therapeutic potential of Tellurium-based compounds alongside its QS200 product candidate for treating diffused axonal injuries, responsible for most traumatic brain injuries. Preliminary studies indicate positive effects against antibiotic-resistant bacteria and sepsis. Qrons plans to advance to pre-clinical and pilot clinical studies to validate findings and expand its intellectual property. The CDC highlights the urgency of addressing these medical conditions, with significant hospitalization and mortality rates.
Qrons Inc. (OTCQB:QRON) announced on April 3, 2022, the filing of a United States Provisional Patent Application for Therapeutic Polypseudorotaxane Hydrogels. This patent aims to provide global protection for inventions targeting central nervous system conditions like traumatic injuries and neurodegenerative diseases. President Ido Merfeld emphasized that the filing reflects their innovative research in neuronal tissue engineering. CEO Jonah Meer stated this patent enhances their intellectual property portfolio and supports their QS200 product candidate development.
Qrons Inc. (OTCQB:QRON) has received SEC approval for its Post-Effective Amendment to the S-1 Registration Statement, which enables an offering of up to 2.5 million shares. This follows the original filing on December 1, 2021. The funds raised will be directed toward advancing technology for neuronal diseases, sales and marketing, patent filing, and general working capital. CEO Jonah Meer stated that these efforts aim to enhance shareholder structure and increase liquidity, supporting plans for a future uplisting. Qrons also emphasizes ongoing commitments to ensure the registration statement remains current.